The iShares MSCI World ETF is cruising near an all-time high, but the next few weeks will test the mechanics of passive investing like rarely before. A potential SpaceX listing, a fresh batch of pharmaceutical tariffs, and a Federal Reserve that has all but ruled out rate cuts are converging on a portfolio already skewed towards US tech giants.
Free-Float Rules Tighten Just as a Mega-IPO Looms
MSCI has quietly tightened its free-float methodology, effective 1 June 2026. The change, announced on 12 May and implemented at the close on 29 May, led to a surge in free-float adjustments during the May rebalancing. The index provider also removed a net 52 companies from the MSCI World in its semi-annual review.
The timing is awkward. SpaceX filed confidentially for an IPO in April, targeting a Nasdaq listing this summer at a valuation of $1.75 trillion. With an issuance volume of $75 billion, it would be the largest initial public offering in history.
MSCI chief Henry Fernandez told Welt am Sonntag that SpaceX could be admitted to MSCI indices just ten trading days after its Nasdaq debut, bypassing the usual three-month waiting period. Under the fast-entry rules, inclusion in the MSCI World could happen within 15 trading days. The estimated index-driven buying pressure: $12 billion. For a passive fund like the iShares MSCI World ETF, that means automatic acquisition—no discretion allowed.
Tariffs Hit the Health-Care Corner
The tariff front adds another layer. The US has imposed a 15% levy on patented pharmaceuticals from the European Union, Japan, South Korea, and Switzerland, while British products face a 10% rate. Companies without existing pricing agreements risk duties of up to 100%. FactSet has already trimmed earnings forecasts for the health-care sector, which accounts for roughly one-tenth of the ETF’s holdings.
Fed Stays Put as Inflation Holds at a Three-Year High
On the monetary policy side, Kevin Warsh took the helm of the Federal Reserve on 15 May and will chair his first meeting on 17 June. Markets assign a 97% probability to no change in rates. US inflation stands at 3.8%—a three-year peak—while wage growth lags at 3.6%. Goldman Sachs and Bank of America have both scrapped their 2026 rate-cut forecasts entirely.
Should investors sell immediately? Or is it worth buying MSCI World ETF?
That matters because the ETF’s portfolio is heavily weighted toward growth stocks that are sensitive to discount-rate shifts. With a price-to-earnings ratio of 25.1, the fund trades at a premium that is largely justified by the tech giants at the top—Nvidia at 5.70%, Apple at 5.05%, Microsoft, Amazon, and Alphabet together representing almost a fifth of assets.
Flows Stay Strong Despite Concentration Risk
Investors have not been deterred. Over the past twelve months, the ETF has attracted net inflows of $1.86 billion, pushing total assets to $7.90 billion. The fund closed at $204.65, up about 4% in 30 days, with a relative strength index of 67.6—approaching overbought territory but not yet alarming.
The sector breakdown shows technology at 30.55%, financials at 15.21%, and industrials at 10.95%. The heavy US tilt—72% of the portfolio—means a SpaceX addition would do little to alter country allocation but would increase reliance on a handful of American growth stories.
Growing Fee Pressure Sparks a Look at Alternatives
Meanwhile, the expense ratio of 0.24% is coming under scrutiny. Invesco has slashed its comparable product to 0.05%, and UBS and BNP Paribas have followed suit. Morningstar still awards the iShares fund a Gold rating, citing a tracking difference of just 0.02%. But investors seeking cheaper or more diversified options can turn to the iShares Core MSCI Total International Stock ETF at 0.07% (which excludes US stocks entirely) or the iShares MSCI ACWI at 0.32% (which adds emerging markets).
The immediate data points on the calendar are the May nonfarm payrolls report on 5 June and Warsh’s first policy decision on 17 June. Either could recalibrate rate expectations. But the most structural test remains the SpaceX IPO. If the rocket company lands on the Nasdaq as anticipated, MSCI will have a swift decision to make—and the iShares MSCI World ETF will have no choice but to follow.
Ad
MSCI World ETF Stock: Buy or Sell?! New MSCI World ETF Analysis from June 4 delivers the answer:
The latest MSCI World ETF figures speak for themselves: Urgent action needed for MSCI World ETF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 4.
MSCI World ETF: Buy or sell? Read more here...
